Cardiovascular Assessment up to One Year After COVID-19 Vaccine–Associated Myocarditis
Myocarditis has been recognized as a complication of COVID-19 mRNA vaccinations, particularly in adolescent and young adult male patients.1 Cardiovascular sequelae after an acute episode of myocarditis, regardless of pathogenesis, remain as issues of concern. Although the reported short-term clinical trajectory after COVID-19 vaccine–associated myocarditis appears reassuring, with resolution of cardiac symptoms and normalization of left ventricular ejection fraction (LVEF) in most of the adolescent patients,2 the long-term cardiovascular outcomes remain unclear.
We evaluated the cardiovascular outcomes at up to 1 year in adolescent patients diagnosed with COVID-19 vaccine–associated myocarditis. Their electrocardiographic, echocardiographic, and cardiac magnetic resonance (CMR) findings at diagnosis were reviewed. At latest follow-up, clinical assessment, ECG, echocardiogram (Vivid E9, GE Medical System, Horten, Norway), and CMR (Siemens Magnetom Aera 1.5 T MRI system, Germany) were performed. The study was approved by the Institutional Review Board and the parents of subjects gave informed consent. Data that support our findings are available from the corresponding authors on reasonable request.
Forty patients (33 male) 15.1±1.6 (range, 12.7–17.9) years of age and followed up for 10.0±1.3 (range, 5.6–12.3) months, representing all cases identified in Hong Kong during the period of study, were included. Twenty-nine (73%) patients were asymptomatic, whereas 7 (18%) reported noncardiac chest pain, 3 (8%) reported palpitations, and 1 (3%) reported fatigue during follow-up, with none having cardiac arrhythmias, angina, or heart failure. The ECG results were abnormal, with ST-segment or T-wave abnormalities in 31 (78%) patients at presentation and normalized in all at latest follow-up.
Echocardiographic assessment at presentation showed normal LVEF in all patients, mild increased echogenicity of the pericardium or left ventricular (LV) lateral wall in 6 (15%), and minimal (<2 mm) pericardial effusion in 2 (5%). At latest follow-up, 38 (95%) patients had normal LVEF, 2 (5%) had borderline LVEF of 51.1% and 53.6%, and all had normal right ventricular (RV) fractional area change. Analyses of RV and LV 4-chamber longitudinal strain were feasible, when ≥5 segments in each plane could be analyzed, in 36 patients and LV global longitudinal and circumferential strain in 35. The LV 4-chamber longitudinal, global longitudinal, and circumferential systolic strain was impaired (Z score <–2) in 8 (22%), 7 (20%), and 4 (11%) patients, respectively. The RV longitudinal systolic strain and early- and late-diastolic strain rates were impaired in 2 (6%), 3 (8%), and 10 (28%) patients, respectively. Mean Z scores of diastolic functional indices of both ventricles were significantly lower than zero (all P<0.002; Figure A). No patients had coronary abnormalities.

Thirty-nine patients had CMR at presentation, 26 of whom had abnormal findings. These included features of myocarditis in 22 (56%), abnormal T1 values in 21 (54%), abnormal T2 values in 24 (62%), late gadolinium enhancement (LGE) in 19 (49%), and reduced LVEF in 7 (18%). The CMR-derived LVEF at initial assessment correlated with LV 4-chamber longitudinal (r=0.36, P=0.04), global longitudinal (r=0.41, P=0.02), and circumferential (r=0.38, P=0.03) absolute systolic strain at follow-up echocardiography. Follow-up CMR performed in 26 patients with initial abnormal CMR findings revealed mild residual LGE in 15 (58%; Figure B), borderline LVEF in 2 (8%), and normal findings in 11 (42%) patients. None of these patients had abnormal T1 (pregadolinium 1013±28 ms and postgadolinium 473±43 ms) or T2 (48±2 ms) values or features of myocarditis. For the patient without initial assessment, follow-up CMR showed mild LGE with normal LVEF. Distribution of LGE in the 16 patients shows predilection of involvement of lateral segments (Figure C). The presence of previous LGE correlated with LGE on follow-up (φ-coefficient=0.71, P<0.001). Patients with (n=16) and those without (n=11) LGE on follow-up CMR had similar demographic and echocardiographic parameters (all P>0.05).
To our knowledge, this is the longest follow-up study to date with comprehensive cardiac evaluation and imaging of adolescent patients diagnosed with COVID-19 vaccine–associated myocarditis. Global systolic ventricular function appears to be preserved. However, impairment of LV and RV myocardial deformation and persistence of LGE in a significant subset of patients with up to 1 year of follow-up was observed. Growing evidence suggests worse prognosis in the presence of altered myocardial deformation and LGE in patients with myocarditis.3 A short-term study reported abnormal CMR-derived LV longitudinal strain and LGE in 70% to 75% of adolescent patients with COVID-19 vaccine–associated myocarditis followed up for 3 to 8 months.4 Similar CMR findings were found in young adults studied at 3 to 6 months after the initial diagnosis.5 The implications of impaired systolic and diastolic myocardial deformation and LGE in our patient subset remain unclear. Nonetheless, given that impaired myocardial deformation and LGE are indicators of subclinical myocardial dysfunction and fibrosis, there exists a potential long-term effect on exercise capacity and cardiac functional reserve during stress.
Limitations of our study include a relatively small patient cohort, the lack of a trajectory that depicts changes in myocardial deformation over time, and performance of CMR only in patients with initial abnormal CMR findings. Further long-term studies to define the clinical and functional implications of these subclinical abnormalities in a larger cohort are undoubtedly warranted.
Footnote
Nonstandard Abbreviations and Acronyms
- CMR
- cardiac magnetic resonance
- LGE
- late gadolinium enhancement
- LV
- left ventricular
- LVEF
- left ventricular ejection fraction
- RV
- right ventricular
REFERENCES
1.
Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, Olsha-Castell S, Arad D, Hasin T, Levi N, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med. 2021;385:2140–2149. doi: 10.1056/NEJMoa2109730
2.
Kracalik I, Oster ME, Broder KR, Cortese MM, Glover M, Shields K, Creech CB, Romanson B, Novosad S, Soslow J, et al; Myocarditis Outcomes After mRNA COVID-19 Vaccination Investigators and the CDC COVID-19 Response Team. Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study. Lancet Child Adolesc Health. 2022;6:788–798. doi: 10.1016/S2352-4642(22)00244-9
3.
Eichhorn C, Greulich S, Bucciarelli-Ducci C, Sznitman R, Kwong RY, Grän C. Multiparametric cardiovascular magnetic resonance approach in diagnosing, monitoring, and prognostication of myocarditis. JACC Cardiovasc Imaging. 2022;15:1325–1338. doi: 10.1016/j.jcmg.2021.11.017
4.
Schauer J, Buddhe S, Gulhane A, Sagiv E, Studer M, Colyer J, Chikkabyrappa SM, Law Y, Postman MA. Persistent cardiac magnetic resonance imaging findings in a cohort of adolescents with post-coronavirus disease 2019 mRNA vaccine myopericarditis. J Pediatr. 2022;245:233–237. doi: 10.1016/j.jpeds.2022.03.032
5.
Patel YR, Shah NR, Lombardi K, Agarwal S, Salber G, Patel R, Poppas A, Atalay MK. Follow-up cardiovascular magnetic resonance findings in patients with COVID-19 vaccination-associated acute myocarditis. JACC Cardiovasc Imaging. 2022;15:2007–2010. doi: 10.1016/j.jcmg.2022.06.009
Information & Authors
Information
Published In
Copyright
© 2023 American Heart Association, Inc.
History
Published online: 31 July 2023
Published in print: 1 August 2023
Keywords
Subjects
Authors
Disclosures
Disclosures None.
Sources of Funding
None.
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
- Design and rationale of the COVID vaccine-associated myocarditis/pericarditis (CAMP) study, American Heart Journal, 281, (32-42), (2025).https://doi.org/10.1016/j.ahj.2024.11.008
- COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign, Cureus, (2024).https://doi.org/10.7759/cureus.52876
- The correlation between the European System for Cardiac Operative Risk Evaluation and the Model for End-Stage Liver Disease in patients with coronary artery bypass graft surgery, Journal of Medicine and Life, 17, 10, (926-933), (2024).https://doi.org/10.25122/jml-2024-0311
- Genome-wide association study of BNT162b2 vaccine-related myocarditis identifies potential predisposing functional areas in Hong Kong adolescents, BMC Genomic Data, 25, 1, (2024).https://doi.org/10.1186/s12863-024-01238-6
- Determinants of COVID-19 vaccine-induced myocarditis, Therapeutic Advances in Drug Safety, 15, (2024).https://doi.org/10.1177/20420986241226566
- COVID‐19 vaccine adverse events: Evaluating the pathophysiology with an emphasis on sulfur metabolism and endotheliopathy, European Journal of Clinical Investigation, 54, 10, (2024).https://doi.org/10.1111/eci.14296
- Gene-based COVID-19 vaccines: Australian perspectives in a corporate and global context, Pathology - Research and Practice, 253, (155030), (2024).https://doi.org/10.1016/j.prp.2023.155030
- Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity, Heliyon, 10, 15, (e34691), (2024).https://doi.org/10.1016/j.heliyon.2024.e34691
- Long-Term Prognosis of Patients With Myocarditis Attributed to COVID-19 mRNA Vaccination, SARS-CoV-2 Infection, or Conventional Etiologies, JAMA, 332, 16, (1367), (2024).https://doi.org/10.1001/jama.2024.16380
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to access the full text.
eLetters(0)
eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.